Progress in surgical treatment of patients with de novo stage IV breast cancer
The incidence of de novo stage IV breast cancer accounts for about 3%-10% of newly diagnosed breast cancer cases. As a malignant metastatic tumor, de novo stage IV breast cancer is incurable. Several studies suggest that the clinicopathologic features and survival prognosis of patients with de novo stage IV breast cancer are different from those of patients with recurrent metastatic breast cancer. The traditional treatment for stage IV breast cancer is mainly systemic therapy, aiming to alleviate symptoms, delay disease progression, and improve the quality of life of patients. In recent years, there has been great controversy over whether resection of the primary lesion can improve the prognosis of patients with de novo stage IV breast cancer. To approach this issue, it is necessary to summarize the retrospective and prospective studies of resection of primary lesions in patients with de novo stage IV breast cancer and to analyze the relevant factors affecting the benefit of surgery for patients. Therefore, clinicians should, based on the actual situation of different patients, comprehensively consider individualized treatment plan in the actual clinical work.
万方数据
